OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
08/20/2026
Back to search
Official data from USPTO
CORENGAGER
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
08/20/2026
Trademark type
Combined
Nice classes
1, 5, 42
Filing date
11/20/2024
Registration date
03/31/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/31/2026
Last transaction
08/20/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
99
Owner location
CN
Examiner
PEISECKI, MARK A
Law office
L50
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Corregene Biotechnology Co., Ltd.
Representatives
Priscilla Lauren Speer Bayramoglu Law Offices LLC
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Protein in raw material form for scientific and medical research; diagnostic reagentsother than for medical or veterinary purposes; diagnostic preparationsother than for medical or veterinary purposes; biochemical preparations for scientific purposes; biological preparations for use in cell culturesother than for medical or veterinary purposes; chemical preparations for scientific purposesother than for medical or veterinary use; diagnostic preparations for research laboratory use; biological preparationsfor use in scientific research and developmentother than for medical or veterinary purposes; biochemical reagents used for non-medical purposes; cell culture reagents for scientific or research purposes
Class 5
Pharmaceutical preparations for detectinganalyzingdiagnosing and treating tumorscancerprecancerous lesionschronic infectionsautoimmune diseasesfatty liverinflammatory bowel diseasecervical neoplasiaviral infectionsmetabolic diseasesimmunodeficiencyosteoarthritisthyroid diseaseglycometabolism diseasebone metabolic diseasegonad diseasekidney diseasecardiovascular diseasehepatic fibrosisanemiainflammation diseaseshepatitis diseaseEpstein-Barr (EB) viruseshormonal diseasesallergicimmune disorderTORCH infections and immunoglobulin diseases; anti-cancer preparations; diagnostic preparations for medical or veterinary purposes; medicines for human purposesmedicines for detectinganalyzingdiagnosing and treating tumorscancerprecancerous lesionschronic infectionsautoimmune diseasesfatty liverinflammatory bowel diseasecervical neoplasiaviral infectionsmetabolic diseasesimmunodeficiencyosteoarthritisthyroid diseaseglycometabolism diseasebone metabolic diseasegonad diseasekidney diseasecardiovascular diseasehepatic fibrosisanemiainflammation diseaseshepatitis diseaseEpstein-Barr (EB) viruseshormonal diseasesallergicimmune disorderTORCH infections and immunoglobulin diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; surgical implants comprised of living tissues; stem cells for medical purposes; vaccines; enzymes for medical purposes; biological preparations for medical purposes for the treatment of tumorscancerprecancerous lesionschronic infectionsautoimmune diseasesfatty liverinflammatory bowel diseasecervical neoplasiaviral infectionsmetabolic diseasesimmunodeficiencyosteoarthritisthyroid diseaseglycometabolism diseasebone metabolic diseasegonad diseasekidney diseasecardiovascular diseasehepatic fibrosisanemiainflammation diseaseshepatitis diseaseEpstein-Barr (EB) viruseshormonal diseasesallergic diseasesimmune disorderTORCH infections and immunoglobulin diseasesinfectious diseasesimmune disease and fibrosis diseases
Class 42
Chemical research; chemical analysis; chemical diagnosis for scientific or medical purposes in the nature of chemical analysis; development and testing of chemical production methods; chemical testing and chemistry consultation services; cosmetic research; bacteriological research; biological research; medical research; medical laboratory servicesfor researchdevelopmenttestinganalysis purposes; clinical trials services for othersincluding the designmanagementmonitoringdata managementanalysisreportingregulatory compliance of clinical trials
Publications
History of USPTO decisions and trademark events.
23 publications found
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/05/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
08/05/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/30/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/31/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
03/31/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/10/2026
PUBO
PUBLISHED FOR OPPOSITION
02/10/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/04/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/16/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/08/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/08/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/08/2026
RFNT
REFUSAL PROCESSED BY IB
08/02/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/13/2025
RFRR
REFUSAL PROCESSED BY MPU
07/13/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/21/2025
CNRT
NON-FINAL ACTION WRITTEN
05/20/2025
DOCK
ASSIGNED TO EXAMINER
05/13/2025
MAFR
APPLICATION FILING RECEIPT MAILED
03/21/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/21/2025
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
03/21/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/06/2025
Continuous trademark protection
Get notified about every new filing that threatens CORENGAGER or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.